

RuSH: Sickle Cell Surveillance and Registry Program

CDR Althea M Grant, PhD
Chief, Epidemiology and Surveillance Branch
Division of Blood Disorders
National Center for Birth Defects and Developmental Disabilities
Centers for Disease Control and Prevention







Outline

- Background / Goals/ Partners
- □ Site Selection
- Data gathering / Data elements
- Evaluation of data collected
- Next Steps: Future expansion of Surveillance and Development of Registry
- Questions







Outline

- Background / Goals/ Partners
- □ Site Selection
- Data gathering / Data elements
- Evaluation of data collected
- Next Steps: Future expansion of Surveillance and Development of Registry
- Questions







Domestic Statistics

- ☐ In the United States, SCD affects approx.
 - **72,000 to 84,000¹ (104,000 to 138,900)**
 - 89,000²
- Among newborn American infants, SCD occurs in approximately
 - 1 in 400 Blacks
 - 1 in 1,400 to 1 in 36,000 Hispanics
 - 1 in 80,000 Whites
- Over 3 million Americans have sickle cell trait
 - 1 in 12 (or 8%) African Americans
- 1 Hassell, K (2009) AJPM (in press)
- 2 Brousseau et. al (2009) American Journal of Hematology







Domestic Statistics

- ☐ The total healthcare cost associated with sickle cell disease is 1.1 billion annually (1)
- □ The number of hospitalizations among adults with sickle cell disease (SCD) in 2004 was 83,149 (2)
- □ The total hospital costs for <u>hospitalizations</u> principally for SCD were approximately \$488 million (2)
- Among those hospital stays principally for SCD, 66 percent were paid by

Medicaid and 13 percent were paid by Medicare (2)







Current Challenges

- Three decades shorter life expectancy
- □ Significant pain and other complications
- Growing population
 - More adults
 - Changing demographics







Current Challenges

- Unknown Prevalence
- Lack of access to specialty care/quality care especially for adults
- Lack of understanding of risk factors and complications over the lifespan
- Lack of understanding the overall impact and barriers to diffusion of effective interventions
- No national coordination of services
- □ Lack of community awareness







Stakeholders

- □ Federal Partners
- Sickle Cell Disease Association of America (SCDAA) and other SCD CBOs
- Thalassemia CBOs
- □ Post-ASPHO SCD Summit Surveillance Action Committee
- □ States
- SCD and Thal Consumer Community









A collaborative effort between NHLBI and CDC working with other Federal and state agencies

- Interagency agreement CDC and NHLBI
- 4 year pilot project
- Two Phases: Planning and Implementation
- Phased implementation plan.







RuSH Objectives

- Develop a hemoglobinopathy surveillance system that will
 - Fill a need for generating statistically sound estimates and to store bio-specimens for use in genetic and genomic analyses
 - Provide data for population-based and clinical studies, health services planning, and policies
- Create an infrastructure that enables the development of registries to monitor health outcomes of hemoglobinopathy patient populations
- Establish a bio-specimen repository for hemoglobinopathies







Public Health Surveillance, 2009

Definition of Public Health Surveillance

"The ongoing systematic collection, analysis, and interpretation, of data on specific health events affecting a population, closely integrated with timely dissemination of these data to those responsible for prevention and control."

- Centers for Disease Control and Prevention







Why do we need public health surveillance?

- Assess burden of disease
- Monitor trends in health
- Identify emerging risks




 Develop, implement, and evaluate disease control and prevention programs









Uses of Public Health Surveillance

- Planning of programs and services for SCD
 - Characterization of the affected population
 - Number of affected individuals
 - Location and types of utilized services/facilities
 - Spectrum of complication and issues experienced/services needed and gaps in services available
 - Nature and number of providers
 - The effectiveness of services, prevention efforts and intervention on populations







Objectives of Surveillance System

□ To describe the ongoing pattern of disease occurrence and to link with public health action

Primary

- Prevalence of hemoglobinopathies by genotype including patients not born in US
- Incidence of hemoglobinopathies using NBS data plus immigrants
- Demographics characteristics and geographic distribution







Objectives of Surveillance System

Secondary


- 1. Disease severity, co-morbidities, and chronic disease complications of persons with hemoglobinopathies;
- 2. Disease and treatment-related infections;
- 3. Reproductive and pregnancy outcomes of hemoglobinopathy patient populations;
- 4. Mortality rates, including case fatality rates for hemoglobinopathies and complications;
- 5. Health care utilization, costs of care, and the geographic variation of specific services








Committee and Working Groups for RuSH





Ongoing

- •Monthly CROC Meetings
- •CDC Weekly RuSH Team Meetings
- •Montly CDC-NHLBI Meetings

RUSH Steering Committee

January 13-14, 2009

- □ Key Recommendations
 - Learn from experience
 - Avoid duplication
 - Modify list of conditions
 - Distinguish surveillance from registry approaches
 - Considering state qualifications and readiness
 - Consider and be responsive to the ethical, legal, and social issues (ELSI).







Community-Based Organizations (CBOs)/Advocacy Groups Panel - Themes

- CBOs should be involved early to start educational process and build trust with clients. They should also be apart of process throughout project.
- CDC needs to clearly articulate how RuSH will benefit the patient and their family
- Avoid a paternalistic approach patients need to be empowered and feel that their participation can make a difference in their families' outcomes







Local and State Health Partners Panel - Themes

- State infrastructure and capacity varies from state to state
- Lack of continuity of care makes accessing adult population difficult
- Participants emphasized that success of RuSH will rely heavily on CBO involvement and their ability to build trust between patients and providers







Request for Information Summary

- □ 6 responses
 - 4 from clinical care institutions,
 - 1 from a private non-profit business organization, and
 - 1 from a blood center.
- 5 respondents described 10 existing data sets
- 1 respondent described a database in the development process.







Request for Information Summary

- Populations:
 - SCD, SC trait, and/or abnormal hemoglobinopathies
 - one database included information related to family members.
- 8 data bases contained clinical information.
- □ 3 databases with linked biospecimens
- The biospecimen collections linked to data bases had specimens from 200-600 patients.
 - The data set with the largest no. of patients had information on approximately 3,500 patients.








Outline

- □ Background / Goals/ Partners
- Site Selection
- Data gathering / Data elements
- Evaluation of data collected
- Next Steps: Future expansion of Surveillance and Development of Registry
- Questions









Ongoing

- •Monthly CROC Meetings
- CDC Weekly RuSH Team Meetings
- •Montly CDC-NHLBI Meetings

Funding Opportunity Announcement

- □ Two Modules
 - Module A: Surveillance of Hemoglobinopathies in States
 - Module B: Capacity Building and Surveillance of Hemoglobinopathies in States with a High Historically Underserved Population
- Eligibility:
 - State governments, territories, NYC and DC
 - Module A: All states
 - Module B: States with
 - □ 14% or more of population below U.S. poverty level
 - At least 20% or more racial/ethnic minorities
 - □ 14% or more of the population who are black or African American







FOA Activities


- Data collection and reporting
- Collaboration
- Data integration
- Dissemination of information
- Evaluation and progress reports








RuSH States, February 2010





Ongoing

- •Monthly CROC Meetings
- •CDC Weekly RuSH Team Meetings
- •Montly CDC-NHLBI Meetings

RuSH TIMELINE 2010 March July November Phone Call Hemoglobinop Site Visit- GA Start with athy Learning September States Collaborative New FOA May Reviewed **Funding for January** Site visit- CA Visit- GA new FOA 2 10 4 11 12 **August** June **February** October **December April** Working FOA #2 CDC funds 6 CDC Releases **Groups Begin Applications** states from 2nd RuSH FOA. recieved FOA Site Visits-Awardee PA,FL,NC Site Visit- MI face-to-face Steering meeting Committee Meeting

RuSH TIMELINE 2010 March July November Phone Call Hemoglobinop Site Visit- GA Start with athy Learning September Collaborative States New FOA May Reviewed **Funding for January** Site visit- CA Visit- GA new FOA 2 10 4 6 11 12 **August** June April October **December February** Working FOA #2 CDC funds 6 CDC Releases **Groups Begin Applications** states from 2nd RuSH FOA. recieved FOA Site Visits-Awardee PA,FL,NC Site Visit- MI face-to-face Steering meeting Committee Meeting

FOA 2010

- State-based Surveillance for Hemoglobinopathies
- Applicants
 - New York
 - Ohio
 - Louisiana
 - Hawaii







RuSH TIMELINE 2010 March July November Phone Call Hemoglobinop Site Visit- GA Start with athy Learning September Collaborative States New FOA May Reviewed **Funding for January** Site visit- CA Visit- GA new FOA 2 10 4 11 12 **August** June October **December February April** Working FOA #2 CDC funds 6 **CDC** Releases **Groups Begin Applications** states from 2nd RuSH FOA. recieved FOA Site Visits-Awardee PA,FL,NC Site Visit- MI face-to -face Steering meeting Committee Meeting

Outline

- □ Background / Goals/ Partners
- □ Site Selection
- Data gathering / Data elements
- Evaluation of data collected
- Next Steps: Future expansion of Surveillance and Development of Registry
- Questions







Collaborative Activities Year 1

- □ Refine state surveillance strategies
- Indicators and Case definition Discussion
- Minimal Dataset Development
- Data Linkage
- Develop Data Sharing and Dissemination Plan







Common Data Sources

- Newborn Screening
- Vital statistics birth and death files
- Medicaid claims
- Hospital discharge data
- Emergency department data
- Clinic-based data for individuals ever in care
- Program Service Data
- Registries
 - Immunization, Stroke, Birth Defects, Cancer







Unique data sources

- □ WIC
- Medicare
- Other Payers
- Data from CBOs
- □ Blood Banks
- School Health
- Registries





Challenges for RuSH surveillance

- Case definition (who's in the dataset?)
 - Thalassemia
 - Sickle cell
- Datasharing/data access
- □ ICD coding validity
 - Need for validation study
- Non-NBS population
 - Thalassemia in most states
 - Adults
- What indicators can you measure ?







Working Group Composition

- □ 10-12 members
- □ Chaired by 1 member of RSC
- 1 member from each site/awardee
- Additional members selected by CDC and NHLBI based on expertise
 - Data Collection and Harmonization WG
 - Clinical and Laboratory WG
 - Community Partnerships and Health Education WG







Outline

- □ Background / Goals/ Partners
- □ Site Selection
- Data gathering / Data elements
- Evaluation of data collected
- Next Steps: Future expansion of Surveillance and Development of Registry
- Questions







Collaborative Activities Year 2

- Plan Program Evaluation
- Surveillance Evaluation
- Data Validation







Outline

- Background / Goals/ Partners
- □ Site Selection
- Data gathering / Data elements
- Evaluation of data collected
- Next Steps: Future expansion of Surveillance and Development of Registry
- Questions







Next Steps

- □ Fund next 2010 FOA
- NHLBI Nutrition and Diet in Surveillance and Registry Studies of Hemoglobinopathies Meeting
- Hemoglobinopathies Learning Collaborative
- Minimal Dataset Development
- Working Groups
 - Address Challenges
 - Development and refinement of case definition
 - Refinement of indicators







Questions?



http://www.cdc.gov/ncbddd/sicklecell/





